Caplyta

Lumateperone, sold under the brand name Caplyta, is a medication used for the treatment of schizophrenia and bipolar depression.[1] It is a butyrophenone atypical antipsychotic developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb.[2] The most common side effects include sleepiness and dry mouth.[3] Lumateperone was approved for medical use in the United States in December 2019,[3][4] and becam... [wikipedia]